#BIO2017 Fireside Chats and Panel Sessions to Cover Breakthrough Topics

As the programming for BIO 2017 continues to take shape, five Fireside Chats are now scheduled that will explore a range of breakthrough topics including investment strategies and pitfalls, the need to ensure patients’ voices in drug development and navigating the drug approval process. Diverse panel sessions promise to challenge and inform. Four tracks are highlighted in this blog: business development, rare diseases, regulatory science and brain health.

Some highlighted Fireside Chats include:

Fireside Chat with Brent Saunders
Chairman, President and Chief Executive Officer, Allergan plc
Monday, June 19 | 2:00–2:45 PM

Join BIO’s President and CEO, Jim Greenwood in a one-on-one discussion with Allergan Chairman, President and CEO, Brent Saunders, who has successfully navigated large, multi-national firms through some of the most complicated transactions to improve the competitive positions of companies.

Fireside Chat with Dean Lloyd Minor, MDStanford University School of Medicine
Monday, June 19 | 3:00–4:45 PM

Join Bloomberg health reporter, Caroline Chen, as she interviews Dr. Lloyd Minor, the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine. Under Minor’s leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in precision health.

Fireside Chat with Dan Skovronsky, MD, PhD, Senior Vice President, Clinical and Product Development, Eli Lilly and Company, Chairman, Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company)
Tuesday, June 20, 4:00 PM – 5:00 PM

Speeding innovative medicines to patients is Dr. Skovronsky’s goal. Join us as we discuss the challenges and rewards of drug discovery, development and approvals to which Dr. Skorvronskly has dedicated his successful career.

Understanding the Patient Voice: Three Unique Perspectives on Healthcare

Wednesday, June 21, 3:00 PM – 4:00 PM

Join a discussion with Paul Hastings, Chairman and Chief Executive Officer, Oncomed Pharmaceuticals, and three patient advocates as they discuss their perspectives on what it means to be a patient and their drive to bring new treatments to those who need them. Speakers include:

  • Emily Kramer-Golinkoff, Co-Founder of Emily’s Entourage and an internationally recognized patient advocate and speaker.
  • Liz Kennerley, Patient and Patient Advocate for the United Mitochondrial Disease Foundation.
  • TJ Sharpe, Patient, Patient Advocate, and writer of Patient #1 blog on Philly.com facing an ongoing battle with stage IV melanoma.

 

Fireside Chat with Kathleen “Kate” Rubins, PhD
Astronaut, NASA
Thursday, June 21 | 11:00–12:00 PM

The first person to sequence DNA in space, Dr. Kate Rubins will discuss her breakthrough outer space experiences and her studies in HIV-1 integration and viral diseases affecting Africa.

Track Spotlight

Business Development, sponsored by EY, GSK

Explore the unique life sciences business landscape from all angles with seasoned professionals highlighting deal structures and models for advancing public-private partnerships, venture capital opportunities for small businesses, lessons on sizing up deals and novel approaches that can transform research breakthroughs into outstanding patient care.

Orphan & Rare Disease, sponsored by CSL Behring

Most rare diseases are genetic, and are present throughout a person’s entire life, even if symptoms do not immediately appear. Learn more about the varying approaches to treating and potentially curing genetic disorders including gene editing and advancements in mRNA therapeutics as well as government initiatives to boost the development of orphan medicines.

Regulatory Science

Discover the opportunities created by the 21st Century Cures Act in advancing innovative drug development and enabling better decisions and outcomes for patients. New drug development tools for various diseases and real world evidence are also top of mind within this track.

Brain Health

From video games as occupational therapy and diagnostic tools to the opioid epidemic, this track covers the compelling science that will address new ways to treat, cure, and even prevent brain disorders.